Skip to main content
Journal cover image

Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.

Publication ,  Journal Article
Choi, T; Kang, Y
Published in: Pharmacol Ther
April 2022

Although treatment outcomes of multiple myeloma patients have improved significantly during the last two decades, myeloma is still an incurable disease. There are newly emerging immunotherapies to treat multiple myeloma including monoclonal antibodies, antibody-drug conjugate, bispecific antibodies, and chimeric antigen receptor (CAR) T cell therapy. Impressive response rate and clinical efficacy in heavily pretreated myeloma patients led to the FDA approval of the first myeloma CAR-T therapy in March 2021. Among many different targets for myeloma CAR-T therapies, B Cell Maturation Antigen (BCMA) has been the most successful target so far, but other targets which can be used either for single-target or dual-target CAR-T's are actively being explored. Clinical efficacy and safety of current myeloma CAR-T therapies will be presented here. Potential mechanisms leading to resistance include clearance of CAR-T cells, antigenic escape, and immunosuppressive tumor microenvironment. Novel strategies to enhance myeloma CAR-T will also be described. In this article, we provide a comprehensive review of the current data and the future directions of myeloma CAR-T therapies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Pharmacol Ther

DOI

EISSN

1879-016X

Publication Date

April 2022

Volume

232

Start / End Page

108007

Location

England

Related Subject Headings

  • Tumor Microenvironment
  • Receptors, Chimeric Antigen
  • Pharmacology & Pharmacy
  • Multiple Myeloma
  • Immunotherapy, Adoptive
  • Humans
  • Cell- and Tissue-Based Therapy
  • B-Cell Maturation Antigen
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Choi, T., & Kang, Y. (2022). Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma. Pharmacol Ther, 232, 108007. https://doi.org/10.1016/j.pharmthera.2021.108007
Choi, Taewoong, and Yubin Kang. “Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.Pharmacol Ther 232 (April 2022): 108007. https://doi.org/10.1016/j.pharmthera.2021.108007.
Choi T, Kang Y. Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma. Pharmacol Ther. 2022 Apr;232:108007.
Choi, Taewoong, and Yubin Kang. “Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.Pharmacol Ther, vol. 232, Apr. 2022, p. 108007. Pubmed, doi:10.1016/j.pharmthera.2021.108007.
Choi T, Kang Y. Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma. Pharmacol Ther. 2022 Apr;232:108007.
Journal cover image

Published In

Pharmacol Ther

DOI

EISSN

1879-016X

Publication Date

April 2022

Volume

232

Start / End Page

108007

Location

England

Related Subject Headings

  • Tumor Microenvironment
  • Receptors, Chimeric Antigen
  • Pharmacology & Pharmacy
  • Multiple Myeloma
  • Immunotherapy, Adoptive
  • Humans
  • Cell- and Tissue-Based Therapy
  • B-Cell Maturation Antigen
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences